New Cancer Treatment Shows Promise Against Aggressive Tumors

Researchers just found a way to attack one of the most aggressive forms of breast cancer from two directions at once.

Scientists at The University of Texas MD Anderson Cancer Center identified an enzyme called RNase H2 that helps triple-negative breast cancer cells survive treatments designed to kill them. By blocking this enzyme, they discovered they could both damage cancer cells directly and wake up the immune system to join the fight.

Triple-negative breast cancer is one of the toughest cancers to treat. It doesn't respond to many standard therapies and tends to grow faster than other breast cancers. About 10 to 15 percent of all breast cancers fall into this aggressive category.

The breakthrough came when researchers noticed that triple-negative tumors produce unusually high amounts of RNase H2. This enzyme acts like a repair crew, fixing DNA damage and helping cancer cells survive treatments that would normally kill them. When the team blocked RNase H2 in lab studies, cancer cells couldn't handle the stress and died.

But the real surprise was what happened next. Blocking the enzyme also triggered the body's immune system to recognize and attack the tumors. DNA damage from the treatment sent out distress signals that recruited T cells, the body's natural cancer fighters, to the tumor site.

Dr. Shiaw-Yih Lin, who led the study published in Cell Reports Medicine, calls it a "one-two punch" that overcomes cancer's survival tricks. The research showed that tumors shrank significantly in laboratory models when RNase H2 was blocked.

Why This Inspires

This discovery opens multiple paths forward for patients. The research showed that blocking RNase H2 also makes existing cancer drugs work better, particularly ATR and PARP inhibitors already used in cancer treatment.

Some RNase H2 inhibitors are already in development, meaning this research could move toward human trials relatively quickly. For patients facing this aggressive cancer, that timeline matters deeply.

The study received support from the National Institutes of Health, the National Cancer Institute, and the Cancer Prevention & Research Institute of Texas, showing strong institutional backing for continued research.

While these results are still preclinical and haven't been tested in human patients yet, they lay important groundwork for new treatment strategies that could meaningfully improve outcomes for people facing this difficult diagnosis.